Fresenius
mAbxience and HP Drive the Use of Artificial Intelligence in Biomanufacturing and Biosimilar Development
mAbxience; HP; artificial intelligence; biomanufacturing; biosimilar development; digital twin; monoclonal antibodies; neural network models; biologics; Fresenius
FDA Tracker: Fresenius Kabi and Formycon’s Stelara Biosimilar Set for 2025 Launch
Stelara biosimilar, Fresenius Kabi, Formycon, FDA approval, ustekinumab, Johnson & Johnson, J&J settlements, biosimilar competition